Boothbay Fund Management LLC Sells 13,748 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Posted by on Mar 4th, 2023

Boothbay Fund Management LLC reduced its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) by 41.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,752 shares of the technology company’s stock after selling 13,748 shares during the quarter. Boothbay Fund Management LLC’s holdings in Cogent Biosciences were worth $295,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Deerfield Management Company L.P. Series C grew its stake in shares of Cogent Biosciences by 267.1% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,876,805 shares of the technology company’s stock valued at $53,009,000 after purchasing an additional 4,275,805 shares during the last quarter. Commodore Capital LP lifted its holdings in Cogent Biosciences by 41.2% in the second quarter. Commodore Capital LP now owns 4,944,708 shares of the technology company’s stock valued at $44,601,000 after buying an additional 1,443,940 shares during the period. FMR LLC lifted its holdings in Cogent Biosciences by 204.8% in the second quarter. FMR LLC now owns 1,254,350 shares of the technology company’s stock valued at $11,314,000 after buying an additional 842,796 shares during the period. Farallon Capital Management LLC lifted its holdings in Cogent Biosciences by 41.7% in the first quarter. Farallon Capital Management LLC now owns 850,000 shares of the technology company’s stock valued at $6,367,000 after buying an additional 250,000 shares during the period. Finally, State Street Corp lifted its holdings in Cogent Biosciences by 11.0% in the second quarter. State Street Corp now owns 694,155 shares of the technology company’s stock valued at $6,261,000 after buying an additional 68,523 shares during the period.

Cogent Biosciences Trading Up 4.9 %

COGT opened at $13.49 on Friday. The firm’s fifty day moving average is $13.19 and its two-hundred day moving average is $13.50. Cogent Biosciences, Inc. has a twelve month low of $3.79 and a twelve month high of $18.07.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on COGT shares. Guggenheim increased their price objective on shares of Cogent Biosciences from $22.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, December 13th. Wedbush cut their price objective on shares of Cogent Biosciences to $19.00 in a report on Wednesday, November 16th. SVB Leerink increased their price objective on shares of Cogent Biosciences from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, January 5th. Finally, Needham & Company LLC started coverage on shares of Cogent Biosciences in a report on Wednesday, December 14th. They issued a “buy” rating and a $24.00 price objective on the stock.

Cogent Biosciences Company Profile

(Get Rating)

Cogent Biosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.

Featured Stories

Institutional Ownership by Quarter for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.